For the first time the BCG vaccine against tuberculosis for newborns is not produced at the Cantacuzino Institute this year, an unprecedented situation for the institution in its 91-year history and it is not known if production will start again next year.

The closure of production lines makes Romania dependent on imports and extremely vulnerable in case of a pandemic. Moreover, the efficiency of imported vaccines is questionable because they have not been tested in Romania or adapted to the Romanian population.

The Cantacuzino Institute, considered “vital” for Romania by former health ministers, is not on the list of strategic objectives.

“The importance of this institute for the Romanian state is a major one, especially now, at a time of geopolitical conflicts. We have had strains for over 80 years [that vaccines are based on] and personnel with very good expertise. This is about the survival and defense of a population,” says Monica Balteanu, head of the lab for autoimmune diseases, who is also vicepresident of the TESA employees trade union.

She has been working for 29 years within the Cantacuzino Institute, one of the 11 international vaccine manufacturers.

“It is of vital importance for Romania,” says in turn former health minister Ritli Ladislau.

2012 is the first year in the institution’s 91-year history when the institution’s manufacturing lines have produced no vaccine and that Romania has had to import both the BCG vaccine against tuberculosis for newborns, and the vaccine against the seasonal flu.

The BCG vaccine carries the risk of adverse effects, while the flu vaccine could not be supplied in sufficient amount in the case of an epidemic, says Balteanu, as does a report of the Ombudsman.

Why the Cantacuzino institute is important

The Ombudsman notes in a report that the World Health Organization recommends the keeping of the same vaccine strain across the same territory. “There is the risk that imported vaccines might not provide protection or might cause adverse reactions,” reads the Ombudsman report.

The report also shows that in the absence of domestic production, the Romanian state would have to import a reserve supply at higher costs, but in a crisis situation foreign producers would prefer to supply their own market first.

The Ombudsman notes that the existence of the Institute is “beneficial” because Romania is not dependent on external producers, production costs are low, new products have emerged thanks to Romanian research, such as Cantastim, Orostim, Bronhodin (which have no correspondent on the external market) and so have new vaccines.

The institute’s current situation

The institute is self-funded, i.e. it finances its activity with money collected from selling vaccines, lab tests and various products that it delivers to state-run hospitals. In the absence of vaccine production, the little money it collects from other activities is not enough to ensure its survival.

“The current sources of funding are the sale of the institute’s own products- around 65%, specialized services to Romanian public healthcare institutions and to the population (on demand – 15%) and national and international research contracts – around 20%. The Health Ministry has remained the main source of funding for the Cantacuzino Institute,” reads the Ombudsman report.

Moreover, the Institute was supposed to pay money to the Health Ministry for vaccine doses that were not delivered.

The employees working in production have been temporarily laid off until the beginning of next year, when both manufacturing lines should become operational again.

How it has come to this

Before the 1989 revolution the Institute delivered over 400 products to Romania and also ensured the reserve of the Health Ministry for emergency situations, according to data provided by Monica Balteanu. It had 1,200 people in production and who provided technical assistance (if diseases or flu appear, tests are sent to the Cantacuzino Institute for identification), research, and vaccine testing.

The period before the Revolution was good for Cantacuzino because “despite the many products and responsibilities we had, we were not short on money.”

The report of the Ombudsman shows that the Institute had an “essential” contribution to the eradication of smallpox, polio, typhoid fever, diphtheria, neonatal tetanus, and reducing morbidity of German measles, the flu and tuberculosis.

Balteanu says about the 1990-2000 period that it was a good time for the Institute and that it had enough money, but that it is then that external producers started to enter the Romanian market and that the ministry started to buy the vaccine from the external market, so the institute’s production was cut.

According to information at the time, in March 2009 the management of the institute decided to suspend the BCG production line (a vaccine against tuberculosis compulsory for newborns) in order to do retooling works scheduled for completion in December 2009.

The works were necessary in order to obtain the Good Manufacturing Practice permit required for any vaccine or drug sold in the EU.

The institute has never had such an accreditation, but until 2009 it functioned based on a waiver passed by the Health Ministry in 2006 for three years. But the works were not finalized within the expected deadline – December 2009 – so the BCG vaccine crisis started.

In the meantime there have been periods when BCG was manufactured based on temporary permits which covered some of the deliveries made in 2011, but afterwards nothing more was manufactured. At present the Health Ministry imports the BCG vaccine.

The second suspended production line with the Institute is one for the seasonal vaccine. According to data in the Ombudsman report, works for this line started in 2006 and entailed investments of around EUR10 million from the World Bank. Works have not been finalized yet.

Monica Balteanu explains that the project was conducted through the World Bank, which organized auctions in order to implement the project, but they were delayed because of the participating companies.

(English version by Daniela Stoican)